Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target lifted by analysts at Canaccord Genuity Group from $8.00 to $8.50 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target indicates a potential downside of 6.90% from […]
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target lifted by analysts at Canaccord Genuity Group from $8.00 to $8.50 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target indicates a potential downside of 6.90% from […]
